Photo source: Geropharm
Wegovy, like its Geropharm analog Semavik Next, has dosages ranging from 0.25 to 2.4 mg weekly. However, Novo Nordisk presented evidence in 2025 of the safety and efficacy of the drug at a 7.2 mg concentration.
Results from two international studies of triple-dose semaglutide – STEP UP (1,400 participants with obesity) and STEP UP T2D (512 patients with obesity and type 2 diabetes) – showed that the increased 7.2 mg dose can achieve approximately 20% weight loss, comparable to newer competing medications.
In January 2026, the United Kingdom became the first country to approve Wegovy at the maximum weekly dose.
Semavik Next is included in Russia's Essential Medicines List (ЖНВЛП), making it significantly more affordable than the original Wegovy, which costs up to $1,000 per monthly course abroad. The Russian analog is already being supplied through government contracts – according to Headway data, from January to October 2025, Geropharm sold 96,000 packages of semaglutide medications worth 459.7 million rubles.
For more about how obesity medication therapy works and the availability of modern drugs in Russia – see the review by Marus Media.
Source: Vademecum
All information on this website is provided for informational purposes only and does not constitute medical advice. All medical procedures require prior consultation with a licensed physician. Treatment outcomes may vary depending on individual characteristics. We do not guarantee any specific results. Always consult a medical professional before making any healthcare decisions.